CHEMI S.P.A.

CHEMI S.P.A. is a factory.

Company Introduction: CHEMI S.P.A.

CHEMI S.P.A. is an Italian pharmaceutical company, not Indian, specializing in the research, development, and manufacturing of Active Pharmaceutical Ingredients (APIs) and advanced intermediates. Established in 1993, it operates primarily as a Contract Development and Manufacturing Organization (CDMO), offering a comprehensive range of services from process development and optimization to industrial-scale production.

Based in Pomezia, Italy, CHEMI S.P.A. is part of the Italfarmaco Group. The company is known for its expertise in complex chemical synthesis, adherence to stringent quality standards, and compliance with international regulatory requirements, including current Good Manufacturing Practices (cGMP) and approvals from major health authorities such such as the FDA. Its facilities are equipped with multi-purpose production plants and advanced analytical laboratories, enabling the company to serve a global clientele with high-quality pharmaceutical raw materials and services. CHEMI S.P.A. focuses on innovation, efficiency, and sustainability in its manufacturing processes.

CHEMI S.P.A. is an Italian company, not an Indian one. It specializes in the development and manufacturing of Active Pharmaceutical Ingredients (APIs) and provides Contract Development and Manufacturing Organization (CDMO) services. While CHEMI S.P.A. does not have manufacturing facilities located in India, its products are sold and supplied globally, including to pharmaceutical companies in the Indian market.

Their product portfolio includes a wide range of APIs across various therapeutic areas such as Antivirals, Oncologicals, Central Nervous System drugs, Cardiovascular drugs, Anti-infectives, Steroids, and Peptides. Specific examples of APIs produced by CHEMI S.P.A. are Azithromycin, Clarithromycin, Telmisartan, Ramipril, Rivaroxaban, Apixaban, Dabigatran Etexilate, Ticagrelor, Posaconazole, Voriconazole, Isavuconazole, Pralatrexate, Pemetrexed, Bortezomib, Carfilzomib, Lenalidomide, Pomalidomide, Thalidomide, Everolimus, Sirolimus, Temsirolimus, Exemestane, Anastrozole, and Letrozole.